利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

39 条记录 (耗时 0.024 秒)

    METHOD FOR MEASURING ANTI-WT1 ANTIBODY
    3.
    发明公开
    METHOD FOR MEASURING ANTI-WT1 ANTIBODY 审中-公开
    VERFAHREN ZUR MESSUNG VON ANTI-WT1-ANTIKÖRPERN

    公开(公告)号：EP2757373A1

    公开(公告)日：2014-07-23

    申请号：EP12832236.9

    申请日：2012-09-13

    申请人： International Institute of Cancer Immunology, Inc. ,  Otsuka Pharmaceutical Co., Ltd.

    发明人： SUGIYAMA, Haruo ,  OJI, Yusuke ,  KATSURAGI, Kiyonori ,  TANAKA, Hideaki ,  SOGO, Shinji ,  GOTO, Yoshihiro ,  OHMOTO, Yasukazu ,  IWATA, Husako

    IPC分类号： G01N33/53 ,  C07K14/82 ,  C12N15/09 ,  A61K39/00 ,  G01N33/574

    CPC分类号： G01N33/574 ,  A61K39/0011 ,  C07K14/82 ,  G01N33/57407 ,  G01N33/57419 ,  G01N33/57426 ,  G01N33/57488 ,  G01N33/6854

    摘要： Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method. The method for measuring an anti-WT1 antibody in a sample includes using a polypeptide having antigenicity to the anti-WT1 antibody selected from a polypeptide comprising the amino acid sequence of positions 294-449 in SEQ ID NO: 1, a partial polypeptide of the polypeptide, and a polypeptide including an amino acid sequence having deletion, substitution, or addition of one to several amino acids in the amino acid sequence constituting each of these polypeptides and/or a polypeptide having antigenicity to the anti-WT1 antibody selected from a polypeptide comprising the amino acid sequence of positions 181-324 in SEQ ID NO: 1, a partial polypeptide of the polypeptide, and a polypeptide including an amino acid sequence having deletion, substitution, or addition of one to several amino acids in the amino acid sequence constituting each of these polypeptides.

    摘要翻译： 本发明涉及一种测定样品中的抗WT1抗体的方法的发明，其能够更准确地测定和评价抗WT1抗体并使用该方法。 用于测量样品中抗WT1抗体的方法包括使用对抗WT1抗体具有抗原性的多肽，所述抗WT1抗体选自包含SEQ ID NO：1中294-449位氨基酸序列的多肽， 多肽和包含在构成每个这些多肽的氨基酸序列中具有1至数个氨基酸的缺失，取代或添加的氨基酸序列的多肽和/或对抗WT1抗体具有抗原性的多肽，所述抗WT1抗体选自多肽 其包含SEQ ID NO：1中的位置181-324的氨基酸序列，多肽的部分多肽，以及包含在氨基酸序列中具有一至几个氨基酸的缺失，取代或添加的氨基酸序列的多肽 构成这些多肽中的每一种。

    METHOD FOR ACTIVATION OF HELPER T CELL AND COMPOSITION FOR USE IN THE METHOD
    7.
    发明公开
    METHOD FOR ACTIVATION OF HELPER T CELL AND COMPOSITION FOR USE IN THE METHOD 有权
    激活中使用的T辅助细胞和组合物的方法中的一种方法

    公开(公告)号：EP2119778A1

    公开(公告)日：2009-11-18

    申请号：EP08712039.0

    申请日：2008-02-27

    申请人： International Institute of Cancer Immunology, Inc.

    发明人： SUGIYAMA, Haruo

    IPC分类号： C12N15/09 ,  A61K38/00 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00 ,  C07K14/82 ,  C07K16/32 ,  C12N15/00 ,  C12Q1/02 ,  G01N33/53

    CPC分类号： G01N33/505 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/55516 ,  C07K14/4748

    摘要： Disclosed are: a method for activating a helper T cell, which comprises the step of adding a WT1 peptide to an antigen-presenting cell to activate the helper T cell, wherein the WT1 peptide is capable of binding to any one selected from an HLA-DRB1*1501 molecule, an HLA-DPB1*0901 molecule and an HLA-DPB1*0501 molecule; a composition for use in the method; a therapeutic and/or prophylactic method for cancer by activating a helper T cell; a pharmaceutical composition for use in the therapeutic and/or prophylactic method; and others.

    摘要翻译： 公开的是：用于激活辅助T细胞，其包括将WT1肽添加至抗原呈递细胞以活化辅助性T细胞的步骤的方法，worin WT1肽是能够结合到从HLA选择的任何一个 DRB1 * 1501分子，HLA-DPB1 * 0901分子和HLA-DPB1 * 0501分子; 在该方法中使用的组合物; 用于通过活化辅助T细胞的癌症的治疗和/或预防方法; 用于治疗性和/或预防方法中使用的药物组合物; 和其他人。

    HLA-A*1101-RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    9.
    发明公开
    HLA-A*1101-RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 有权
    HLA-A * 1101限制性WT1肽及包含其的药物组合物

    公开(公告)号：EP3026115A1

    公开(公告)日：2016-06-01

    申请号：EP15201329.8

    申请日：2007-12-14

    申请人： International Institute of Cancer Immunology, Inc.

    发明人： SUGIYAMA, Haruo

    IPC分类号： C12N15/12 ,  A61K31/7088 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  A61P35/02 ,  C07K14/82 ,  C12Q1/02 ,  G01N33/574 ,  C12N15/00

    CPC分类号： A61K39/0011 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/57 ,  A61K2039/572 ,  C07K14/4748 ,  G01N33/574

    摘要： The present invention relates to an HLA-A*1101-restricted WT1 peptide, specifically, a peptide comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein, wherein the peptide has an ability to bind to an HLA-A*1101 molecule, and has an ability to induce a CTL. The present invention also relates to a peptide dimer having an ability to bind to an HLA-A*1101 molecule and having an ability to induce a CTL, in which two peptide monomers each comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein and comprising at least one cysteine residue are bound to each other through a disulfide bond. Furthermore, the present invention relates to a polynucleotide encoding the peptide, a pharmaceutical composition for the treatment and/or prevention of a cancer comprising the same and the like.

    摘要翻译： 本发明涉及HLA-A * 1101限制性WT1肽，具体而言，涉及包含由来自WT1蛋白的9个连续氨基酸组成的氨基酸序列的肽，其中所述肽具有结合HLA-A * 1101分子，并具有诱导CTL的能力。 本发明还涉及具有与HLA-A * 1101分子结合并且具有诱导CTL能力的肽二聚体，其中两个肽单体各自包含由9个连续氨基酸组成的氨基酸序列 包含至少一个半胱氨酸残基的WT1蛋白通过二硫键彼此结合。 此外，本发明涉及编码所述肽的多核苷酸，用于治疗和/或预防包含所述肽的癌症的药物组合物等。